The Europe brain aneurysm treatment market is expected to reach US$ 1,768.43 Mn by 2027 from US$ 644.84 Mn in 2019. The market is anticipated to grow at a CAGR of 13.6% from 2020 to 2027.
The growth of the Europe brain aneurysm treatment market is ascribed to the growing prevalence of neurological disorders, and increasing research and development to boost product innovation for better diagnosis. However, high cost associated with the procedure hampers the growth of market in this region.
The prevalence of brain aneurysms is rising in many European countries. For instance, in France, ~2.5% of the adult population suffers intracranial aneurysms. Further, certain strategic initiatives by the government to treat patients suffering from brain aneurysm are also driving the growth of the brain aneurysm market in Europe. For instance, the French government implemented analysis of treatment by endovascular approach of nonruptured aneurysms. The program was conducted to check the feasibility of endovascular approach for the treatment of nonruptured brain aneurysms.
The Europe brain aneurysm treatment market, based on type, is segmented into surgery and medication. In 2019, the medication segment held a larger share of the market; however, the surgery segment is expected to register a higher CAGR in the market during the forecast period. The Europe brain aneurysm treatment market, based on condition, is segmented into unruptured aneurysm and ruptured aneurysm. In 2019, unruptured aneurysm held a larger share of the market; however, the ruptured aneurysm segment is expected to register a higher CAGR during 2020-2027. Further, the Europe brain aneurysm treatment market, based on end user, is segmented into hospitals and clinics. In 2019, the hospitals segment held a larger share of the market; however, the market for the clinics segment is expected to grow at a higher CAGR during the forecast period.
A few of the major primary and secondary sources involved in the process of preparing the report on the brain aneurysm treatment market are the World Health Organization, European Federation of Pharmaceuticals Industries Associations, and European Medical Association.
Reasons to Buy
The growth of the Europe brain aneurysm treatment market is ascribed to the growing prevalence of neurological disorders, and increasing research and development to boost product innovation for better diagnosis. However, high cost associated with the procedure hampers the growth of market in this region.
The prevalence of brain aneurysms is rising in many European countries. For instance, in France, ~2.5% of the adult population suffers intracranial aneurysms. Further, certain strategic initiatives by the government to treat patients suffering from brain aneurysm are also driving the growth of the brain aneurysm market in Europe. For instance, the French government implemented analysis of treatment by endovascular approach of nonruptured aneurysms. The program was conducted to check the feasibility of endovascular approach for the treatment of nonruptured brain aneurysms.
The Europe brain aneurysm treatment market, based on type, is segmented into surgery and medication. In 2019, the medication segment held a larger share of the market; however, the surgery segment is expected to register a higher CAGR in the market during the forecast period. The Europe brain aneurysm treatment market, based on condition, is segmented into unruptured aneurysm and ruptured aneurysm. In 2019, unruptured aneurysm held a larger share of the market; however, the ruptured aneurysm segment is expected to register a higher CAGR during 2020-2027. Further, the Europe brain aneurysm treatment market, based on end user, is segmented into hospitals and clinics. In 2019, the hospitals segment held a larger share of the market; however, the market for the clinics segment is expected to grow at a higher CAGR during the forecast period.
A few of the major primary and secondary sources involved in the process of preparing the report on the brain aneurysm treatment market are the World Health Organization, European Federation of Pharmaceuticals Industries Associations, and European Medical Association.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe brain aneurysm treatment market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe brain aneurysm treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
3. Research Methodology
4. Brain Aneurysm Treatment - Market Landscape
5. Europe Brain Aneurysm Treatment Market - Industry Dynamics
6. Brain Aneurysm Treatment Market - Regional Analysis
7. Brain Aneurysm Treatment Market Analysis - By Type
8. Brain Aneurysm Treatment Market - By Condition
9. Brain Aneurysm Treatment Market - By End User
10. Brain Aneurysm Treatment Market- Regional Analysis
11. Impact of COVID-19 Pandemic on Europe Brain Aneurysm Treatment Market
12. Brain Aneurysm Treatment Market - Industry Landscape
13. Company Profiles
14. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Stryker Corporation
- MicroPort Scientific Corporation
- Terumo Corporation
- Penumbra, Inc.
- Medtronic
- Johnson & Johnson Services, Inc.
- KANEKA CORPORATION
- Mizuho Medical Co,Ltd.
- adeor medical AG
- Evasc Medical Systems Corp.
